CORRIGENDUM

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

K Schmiegelow, E Forestier, M Hellebostad, M Heyman, J Kristinsson, S Söderhäll and M Taskinen on behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO)

Leukemia (2010) 24, 670; doi:10.1038/leu.2010.10

Correction to: *Leukemia* (2010) 2, 345–354; doi:10.1038/leu.2009.251 The authors apologize for any inconvenience caused.

Since the publication of this paper, the authors have noticed an error in Table 1. The correct version is shown below.

Table 1 Treatment results according to presenting features in patients treated in Study NOPHO ALL-2000

Factors	No. of patients	Event-free survival $\pm$ s.e. (%)				Overall survival $\pm$ s.e. (%)			
		Year 5	Year 10	Year 15	P-value	Year 5	Year 10	Year 15	P-value
<i>B-lineage</i>									
NCI standard	645	85.0 $\pm$ 1.7	—	—	<0.001	95.0 $\pm$ 1.0	—	—	<0.001
NCI high	261	72.1 $\pm$ 3.3	—	—		82.3 $\pm$ 3.0	—	—	
<i>T-lineage</i>									
NCI standard	31	72.6 $\pm$ 8.3	—	—	0.24	78.6 $\pm$ 7.8	—	—	0.378
NCI high	84	61.4 $\pm$ 5.4	—	—		69.4 $\pm$ 5.3	—	—	
<i>Sex</i>									
Male	569	78.2 $\pm$ 2.0	—	—	0.36	88.9 $\pm$ 1.6	—	—	0.915
Female	454	80.8 $\pm$ 2.1	—	—		89.5 $\pm$ 1.6	—	—	
<i>Age at diagnosis (years)</i>									
1–9	840	81.2 $\pm$ 1.6	—	—	0.001	91.1 $\pm$ 1.1	—	—	<0.001
> 10	183	70.6 $\pm$ 4.0	—	—		80.1 $\pm$ 3.6	—	—	
<i>WBC $\times 10^9/l$</i>									
< 10	482	84.1 $\pm$ 2.0	—	—	<0.001	94.0 $\pm$ 1.3	—	—	0.0001
10–49	327	79.9 $\pm$ 2.6	—	—		90.3 $\pm$ 1.9	—	—	
50–99	96	74.3 $\pm$ 4.9	—	—		84.4 $\pm$ 4.1	—	—	
> 100	118	62.5 $\pm$ 4.7	—	—		70.3 $\pm$ 4.8	—	—	
<i>Cell lineage</i>									
B	906	81.3 $\pm$ 1.5	—	—	<0.001	91.4 $\pm$ 1.1	—	—	<0.001
T	115	64.3 $\pm$ 4.5	—	—		71.9 $\pm$ 4.4	—	—	
<i>CNS status</i>									
CNS 1+2	990	80.0 $\pm$ 1.5	—	—	0.004	89.6 $\pm$ 1.1	—	—	0.018
CNS 3	30	63.3 $\pm$ 9.7	—	—		76.7 $\pm$ 8.9	—	—	
<i>HeH (> 50 chr)</i>									
Yes	321	0.84 $\pm$ 0.02	0.08	0.93 $\pm$ 0.02	NS	0.93 $\pm$ 0.02	NS	NS	NS
No	473	0.76 $\pm$ 0.02				0.87 $\pm$ 0.02			
Unknown	229	0.80 $\pm$ 0.03				0.89 $\pm$ 0.02			
<i>DNA index</i>									
> 1.10	43	0.76 $\pm$ 0.08	NS	0.90 $\pm$ 0.05	NS	0.90 $\pm$ 0.05	NS	NS	NS
$\leq$ 1.10	93	0.76 $\pm$ 0.05				0.88 $\pm$ 0.04			
Unknown	887	0.80 $\pm$ 0.02				0.89 $\pm$ 0.01			
<i>t(9;22)</i>									
Present	9	0.44 $\pm$ 0.17	0.01	0.78 $\pm$ 0.14	NS	0.78 $\pm$ 0.14	NS	NS	NS
Absent	786	0.79 $\pm$ 0.02				0.89 $\pm$ 0.01			
Unknown	228	0.82 $\pm$ 0.03				0.89 $\pm$ 0.02			
<i>t(1;19)</i>									
Present	26	0.82 $\pm$ 0.08	NS	0.87 $\pm$ 0.07	NS	0.87 $\pm$ 0.07	NS	NS	NS
Absent	769	0.79 $\pm$ 0.02				0.89 $\pm$ 0.01			
Unknown	228	0.81 $\pm$ 0.03				0.89 $\pm$ 0.02			
<i>ETV6-RUNX1</i>									
Present	201	0.86 $\pm$ 0.03	<0.001	0.96 $\pm$ 0.02	<0.001	0.96 $\pm$ 0.02	<0.001	<0.001	<0.001
Absent	666	0.77 $\pm$ 0.02				0.88 $\pm$ 0.01			
Unknown	256	0.81 $\pm$ 0.04				0.86 $\pm$ 0.03			
<i>t(4;11)</i>									
Present	9	0.20 $\pm$ 0.17	<0.001	0.36 $\pm$ 0.19	<0.001	0.36 $\pm$ 0.19	<0.001	<0.001	<0.001
Absent	785	0.80 $\pm$ 0.02				0.90 $\pm$ 0.01			
Unknown	229	0.80 $\pm$ 0.03				0.89 $\pm$ 0.02			
<i>MRD day 29</i>									
5%	55	0.45 $\pm$ 0.07	<0.001	0.60 $\pm$ 0.08	<0.001	0.60 $\pm$ 0.08	<0.001	<0.001	<0.001
≥ 0.1 –<5%	195	0.74 $\pm$ 0.04				0.90 $\pm$ 0.03			
<0.1%	497	0.86 $\pm$ 0.02				0.93 $\pm$ 0.01			
No MRD analysis	276	0.77 $\pm$ 0.01				0.87 $\pm$ 0.01			